
Stores announced for this year's Boardwalk Shops program in Batavia
Shops focusing on international baked goods, tabletop games and African and Caribbean products are among the stores that will be part of this year's Boardwalk Shops program in Batavia.
The Batavia MainStreet group recently announced the participants in this year's program, a business incubator initiative that is now in its sixth year.
Over half a decade ago, small 12-foot by 12-foot shops were made available at 114 E. Wilson St. in Batavia as part of the program. The first year included eight businesses and has increased to 10 since then.
The Batavia MainStreet group has seen many of the small, fledgling mom-and-pop business that have taken part in the Boardwalk Shops program move on to have brick-and-mortar sites of their own.
Batavia MainStreet Executive Director Beth Walker said momentum in the program continues and that a total of over 20 businesses submitted proposals this year with 10 being selected to take part.
'We started taking applications in September of last year. We had over 20 apply and we had about 30 the year before but we still had good candidates,' she said. 'As far as applications dropping a bit, if you look at the cycle of a small business, it's usually four to five years that it lasts and coming out of COVID, we had a lot of people that started micro-businesses, and a lot of those had to make a decision about whether to go back into the regular work force.'
Walker said this year's collection of shops are 'a great 10. I think it's unique.'
'As we get more retail in downtown Batavia, we're very mindful not to overlap with our existing businesses,' she said. 'This year, we're really happy. We have two that are returning with things that they continue to want to work on and grow their business before they go into a brick-and-mortar.'
The returning businesses are Jodi Mac Sweets & Treats and Scout & Gem, which offers jewelry and home decor.
'We have some other interesting things including a pet food store and a couple that are coming in from Chicago with Guatemala roots that will be selling Guatemalan goods and graphic designs (Giron Guatemalan Apparel + Home), and a lady from Africa who will be having an African market,' Walker said of this year's shops.
Other entries include Tabletop Game Shop, which is bringing its third location to Batavia, as well as A Rooted Home selling home goods and Jaclyn Sue Boutique featuring women's clothing.
'We also have a bakery (AHA Kapeh Traditional Bread) who will sell international baked goods, so that's exciting,' Walker said.
'We also have Stitched by Stephanie,' whose owner has 'an interesting story,' Walker said. 'She's a young woman who sells crocheted stuffed animals but she just turned 21 and has been doing this for four years and is looking to grow her business.'
Walker said there have been pet supply purveyors before at the Boardwalk Shops but the new Pet Wants business offers 'wholesome food for your dog, snacks and some pet supply goods.'
The new Kumba African Market is also unique, she said. Walker said the owner 'is a refugee from Africa and she had a store in Wheaton and is trying out a different market in Batavia.'
Walker said while the Boardwalk Shops program is an incubator in nature, 'it serves two purposes.'
'It's a destination for downtown. We love that it continues to be a destination to draw people from outside Batavia and we hope they will continue to shop the other businesses,' she said. 'It fills in a lot of vacancies we have in downtown. It's really changed that and we're really happy for that.'
Opening day for the Boardwalks Shops this year is May 9.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Ramey v. Penn State University: Class action lawsuit payments distributed to students
(WHTM) – Penn State University students who were enrolled in classes at the start of the COVID-19 pandemic are now receiving part of a $17 million class action settlement. On March 16, 2020, the university moved to 'remote instruction' due to the outbreak of COVID-19. Years later, a class action lawsuit was brought on behalf of those who paid tuition and/or fees for the Spring 2020 semester and registered for a class. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now The lawsuit was brought forward with allegations of a breach of contract by the university for not providing the services promised with tuition and fees. The university denied the claims asserted against it and agreed to the $17 million settlement for students who opted in to the lawsuit, known as 'Ramey et al. v. The Pennsylvania State University.' A court granted final approval of the settlement on February 18, 2025, and the deadline to file a claim has since passed. According to the Penn State Tuition Refund Settlement website, payments to eligible class members were sent on June 5, 2025. The website says those who opted to receive payments should have received notification of their award via email and should expect a check in the mail. Payments were automatically sent to the recipients' 'last known permanent postal address on file with Penn State,' according to the settlement website. The deadline to change that address or type of payment has also passed. Of the $17 million in settlement funds, the final judgment awarded attorneys' fees of $5,666,100, deducted litigation expenses worth $17,990.94, and made a $15,000 award for the individuals who initiated the lawsuit. The remaining portion of the money (approximately $11,300,909) was designated as the 'Net Settlement Fund.' Students eligible for payments 'who withdrew for medical reasons from Penn State after March 16, 2020, but before the conclusion of the Spring 2020 semester, and received a refund of tuition,' will receive $50 from the Net Settlement Fund. The remaining funds were then 'distributed equally to all other Settlement Class Members.' Eligible students included those attending branch campuses at the time of the shutdown, according to the settlement. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. COVID vaccine maker BioNTech is buying rival CureVac, announcing Thursday an all-stock deal weeks before the two companies were due to face off in a German court over potentially billions of dollars worth of royalties related to intellectual property on messenger RNA drugs. Per deal terms, each CureVac share will be exchanged for about $5.46 worth of BioNTech's U.S.-listed shares, valuing the company at $1.25 billion. Upon the deal's close, CureVac shareholders will own between 4% and 6% of BioNTech. In the early days of the COVID-19 pandemic, BioNTech and CureVac were among the companies racing to develop the first coronavirus vaccines. BioNTech, however, partnered with Pfizer and won approval of the first COVID-19 shot, while CureVac's program never made it to market. The two companies have since been embroiled in patent litigation. CureVac was a leading candidate to develop the first COVID-19 vaccine, launching rumors, later denied, that the U.S. government might even buy the company or its research. But while BioNTech and fellow mRNA drugmaker Moderna succeeded in making vaccines that saved millions of lives and earned billions of dollars in revenue, CureVac fell short. Its initial project wasn't effective enough at preventing sickness, prompting it to scrap development. A year later, CureVac sued BioNTech, claiming it infringed four patents. CureVac has since changed course, selling off most rights to influenza and COVID-19 vaccines to partner GSK and focusing on cancer instead. But its legal spat with BioNTech has lingered. The European Patent Office had upheld two CureVac patents, and a trial in a Dusseldorf regional court was set on July 1 to determine if BioNTech had infringed on them. A separate trial in the U.S. was scheduled to begin Sept. 8 in Virginia. Some Wall Street analysts, as a result, speculated that BioNTech's primary purpose is buying CureVac is to sidestep the risk of a loss in court. A single-digit percentage royalty awarded to CureVac could've cost BioNTech as much as $3 billion, Evercore ISI analyst Umer Raffat wrote in a note to clients. 'It seems to us that [BioNTech] assessed the cost of a cash settlement as substantially greater than the cost of buying [CureVac] outright,' Raffat wrote. The deal could also help BioNTech further its oncology ambitions. Like CureVac, BioNTech has made cancer research a top priority. It's invested in a variety of programs, from cell therapies to mRNA vaccines and a coveted type of bispecific antibody. Some are in advanced testing. CureVac's cancer vaccines are in earlier phases of development. A brain cancer shot has delivered early clinical data, while a lung cancer immunotherapy was cleared in April for human testing. The deal should help CureVac because of 'the early stage of the oncology pipeline and the need for a development partner to effectively compete in personalized cancer vaccines – which [BioNTech] is well positioned to execute,' wrote Leerink Partners analyst Mani Foroohar. Raffat, of Evercore ISI, however, wrote that the deal ascribes 'very little value' to CureVac's pipeline. Recommended Reading Recursion to acquire two Canadian drug discovery startups Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
MultiChoice Group Ltd (MCHOY) (FY 2025) Earnings Call Highlights: Strategic Growth Amidst ...
Release Date: June 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MultiChoice Group Ltd (MCHOY) achieved 3.7 billion rand in cost savings, surpassing their target and nearly doubling the previous year's savings. The company reported encouraging growth in new revenue lines such as DSTV Internet, DSTV 3, Kingmakers, and Showmax. Showmax saw a 44% growth in active paying subscribers, gaining market share despite initial challenges. The company maintained a healthy cash balance of 5.1 billion rands, with access to additional undrawn banking facilities. MultiChoice Group Ltd (MCHOY) is strategically positioned to benefit from the long-term growth potential of the African continent, with a focus on expanding streaming and interactive entertainment services. The company experienced an 8% decline in its linear customer base, with active subscribers dropping to 14.5 million. Foreign currency depreciation, particularly in Nigeria, led to a 5.2 billion rand currency impact on the top line. Showmax's growth lagged initial targets, and the company is critically reviewing its business plan due to slower than expected demand. The South African economy's challenges, including high unemployment and low economic growth, negatively impacted MultiChoice's discretionary services. The company's reported trading profit was materially down year on year, impacted by foreign currency pressures and investment in Showmax. Warning! GuruFocus has detected 8 Warning Signs with MCHOY. Q: How are you thinking about price increases across your customer segments for South Africa and the rest of Africa given the pressure you're seeing on the subscriber base? A: Our view is to align price increases with inflation. We believe there is good value in our product at various price levels. However, due to high inflation in many markets, we expect these increases to impact subscriber data. We are seeing stability in foreign currency, which should help consumers adjust to current pricing levels. Q: Can you explain the difference in decoder purchases between South Africa and the rest of Africa? A: In the rest of Africa, particularly Nigeria, we reduced subsidies to offset currency impacts and consumer distress. In South Africa, we are balancing economic outcomes while moving towards removing subsidies, especially with alternatives like DSTV stream available. Q: Can you provide insight into the cost trajectory for Showmax this year? A: There is an element of startup costs, with $70 million invested in platform development. The rest are ongoing costs. Subscriber growth hasn't met expectations, and we are working on initiatives to reduce costs materially. Price increases will depend on market take-up and competitor actions. Q: After increasing prices for Showmax, did you see any change in subscriber activity? A: The trend has been cyclical as expected, with no material change in subscriber activity following the price increase. Q: Can you expand on group subscriber trends and whether attrition will continue or stabilize? A: Year-on-year, this year is better than last. However, the end of the English Premier League season typically sees a decline. Higher decoder prices mean fewer subscribers, but those who pay tend to stay longer, which is favorable during this period. Q: What are the expectations for Showmax subscriber growth, and why hasn't it met initial expectations? A: Broadband pricing assumptions haven't materialized, slowing subscriber growth. Macroeconomic conditions have also impacted us. We are revising our business plan to align with market realities. Q: What is the status of regulatory approvals for the proposed acquisition by Canal Plus? A: We need approvals from several countries, and things are progressing as expected. We anticipate receiving the necessary support before the long-stop date of October 8th. Q: Why was the MultiChoice South Africa dividend reduced despite profitability? A: The macroeconomic situation necessitates a cautious approach to capital preservation and debt management. Despite cost reductions, the South African business has lost subscribers and revenue. We need to support the balance sheet and ensure long-term sustainability. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤